DHA trial: Docosahexaenoic acid (DHA) (omega-3) to improve live birth rate in women with previous miscarriage (PREMIS-DHA)

Research summary

Definitive primary objective: To test the hypothesis that docosahexaenoic acid (DHA) plus eicosapentaenoic acid (EPA) [LP(aSS3.1][EF3.2][AD3.3](omega-3) supplementation at two different doses,used alone,increases the rate of live birth ≥ 34 weeks of gestation by at least 8% in women who have experienced two or more miscarriages. Intermediate primary objective: To test the hypothesis that docosahexaenoic acid (DHA) plus eicosapentaenoic acid (EPA) (omega-3) supplementation at two different doses,used alone,increases the rate of ongoing pregnancy,at 11-14weeks,by at least 10% in women who have experienced two or more miscarriages.

Principal Investigator

Pedro Melo

Contact us

Email: osprea@wrh.ox.ac.uk

IRAS number

1011519